Brand Name(s):Lynparza

Indication:Cancer- adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy



Review Date:May-26

NICE TA693 Olaparib plus bevacizumab is recommended, within the Cancer Drugs Fund for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults when certain criteria are met.
April 21

NICE guidance on olaparib (Lynparza) for treating BRCA mutation?positive, advanced ovarian, fallopian tube or primary peritoneal cancer that has responded to first-line platinum-based chemotherapy in adults; https://www.nice.org.uk/guidance/ta598 …………………………………. NICE TA381
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.
Full information at:http://www.nice.org.uk/guidance/ta381/resources/olaparib-for-maintenance-treatment-of-relapsed-platinumsensitive-brca-mutationpositive-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-secondline-or-subsequent-platinumbased-chemothera-82602844667845